Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Lois M Hinman"'
Autor:
Dan Shochat, Carl F. Beyer, Janis Upeslacis, Lois M Hinman, Delores Lindh, Hamann Philip Ross, Andrew Mountain
Publikováno v:
Bioconjugate Chemistry. 16:354-360
Murine CTM01 is an internalizing murine IgG(1) monoclonal antibody that recognizes the MUC1 antigen expressed on many solid tumors of epithelial origin. Calicheamicin conjugates of this antibody have previously been shown to be potent, selective anti
Autor:
Lois M. Hinman, Philip R. Hamann, Irwin D. Bernstein, Carl F. Beyer, Delores Lindh, Janis Upeslacis, David A. Flowers
Publikováno v:
Bioconjugate Chemistry. 13:40-46
The anti-CD33 antibody, P67.6, has been chosen to target the potently cytotoxic calicheamicin antitumor antibiotics to acute myeloid leukemia (AML) due to the presence of CD33 on >80% of patient samples and its lack of expression outside the myeloid
Autor:
Lee M. Greenberger, Clara Lin, Rosalyn Wallace, Lois M Hinman, Carl F. Beyer, Delores Lindh, Janis Upeslacis, Hamann Philip Ross, Frederick E. Durr, Ana T. Menendez
Publikováno v:
Bioconjugate chemistry. 16(2)
The anti-MUC1 antibody, CTM01, has been chosen to target the potently cytotoxic calicheamicin antitumor antibiotics to solid tumors of epithelial origin that express this antigen. Earlier calicheamicin conjugates relied on the attachment of a hydrazi
Autor:
Ryan Holcomb, Lois M. Hinman, William Hallett, Dan Shochat, Janis Upeslacis, Irwin D. Bernstein, Hwei Ru Tsou, Hamann Philip Ross, Andrew Mountain, David A. Flowers, Irwin Hollander, Carl F. Beyer, Delores Lindh
Publikováno v:
Bioconjugate chemistry. 13(1)
CD33 is expressed by acute myeloid leukemia (AML) cells in >80% of patients but not by normal hematopoietic stem cells, suggesting that elimination of CD33(+) cells may be therapeutically beneficial. A conjugate of a calicheamicin hydrazide derivativ
Autor:
Lois M Hinman, Geoff Yarranton
Publikováno v:
Annual Reports in Medicinal Chemistry ISBN: 9780120405282
Publisher Summary Despite a great deal of research, only a small number of MoAb-based products have been approved for clinical use, including OKT3, a murine IgG for the treatment of renal transplant rejection and myoscint, an in-labeled murine antimy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dacfadc2ec6039c1a4fe76a36dfa83a5
https://doi.org/10.1016/s0065-7743(08)60895-7
https://doi.org/10.1016/s0065-7743(08)60895-7
Publikováno v:
Journal of the American Chemical Society. 96:7067-7073
Autor:
Lois M Hinman, Janis Upeslacis
Publisher Summary This chapter discusses the chemistry behind conjugation of agents to MoAb's. Recent reviews dealing with other aspects of MoAb-based therapy have appeared, covering subjects, such as the generation of hybridomas, the various tumor-a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c37a53455442433b40822a50ff530cb5
https://doi.org/10.1016/s0065-7743(08)60844-1
https://doi.org/10.1016/s0065-7743(08)60844-1
Publikováno v:
Chemischer Informationsdienst. 6
Publikováno v:
Annals of the New York Academy of Sciences. 573
Publikováno v:
Journal of molecular biology. 94(4)
Fully exposed aromatic amino acid side chains on the surface of proteins can act as donors in the formation of π D −π A ∗ charge transfer complexes with the acceptor 1-methyl-3-carbamidopyridinium chloride (1-methylnicotinamide chloride) (Hinma